Publications

ACCURATE PRECLINICAL TRIALS OF NEW EPENDYMOMA THERAPIES

Authors: N Boulos, J Dapper, Y Patel, M DeCuypere, B Bianski, T Merchant, B Freeman,...

Research group: Gilbertson Group

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

MEDULLOBLASTOMA GENOTYPE DICTATES BLOOD BRAIN BARRIER PHENOTYPE

Authors: T Phoenix, D Patmore, S Boop, N Boulos, M Jacus, Y Patel, M Roussel, D Fink...

Research group: Gilbertson Group

E-pub date: 1 Jun 2016

Journal name: NEURO-ONCOLOGY

Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.

Authors: CL Sutherell, C Tallant, OP Monteiro, C Yapp, JE Fuchs, O Fedorov, P Siejka...

Research group: Brenton Group

E-pub date: 26 May 2016

Journal name: J Med Chem

CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.

Authors: J Garcia-Corbacho, F Mouliere, H Carr, JA Morris, F Marrass, DG Gale, S Kum...

Research group: Brenton Group, Rosenfeld Group

E-pub date: 20 May 2016

Journal name:

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

Authors: CA Parkinson, D Gale, A Piskorz, C Hodgkin, H Biggs, H Addley, P Moyle, S F...

Research group: Brenton Group, Rosenfeld Group

E-pub date: 20 May 2016

Journal name: Journal of Clinical Oncology

PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).

Authors: C Gourley, J Green, H Gabra, I Vergote, B Basu, JD Brenton, U Björklund, A...

Research group: Brenton Group

E-pub date: 20 May 2016

Journal name: Journal of Clinical Oncology

Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).

Authors: RL Coleman, EM Swisher, AM Oza, CL Scott, H Giordano, KK Lin, GE Konecny, A...

Research group: Brenton Group

E-pub date: 20 May 2016

Journal name: Journal of Clinical Oncology

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.

Authors: A Piskorz, KK Lin, JA Morris, E Mann, AM Oza, RL Coleman, DM O'Malley, M Fr...

Research group: Brenton Group

E-pub date: 20 May 2016

Journal name: Journal of Clinical Oncology

Filters

Research Groups

Core Facilities

Start date

End date

ACCURATE PRECLINICAL TRIALS OF NEW EPENDYMOMA THERAPIES

MEDULLOBLASTOMA GENOTYPE DICTATES BLOOD BRAIN BARRIER PHENOTYPE

Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.

CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).

Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.

Themes

Filters

Research Groups

Core Facilities

Start date

End date

ACCURATE PRECLINICAL TRIALS OF NEW EPENDYMOMA THERAPIES

MEDULLOBLASTOMA GENOTYPE DICTATES BLOOD BRAIN BARRIER PHENOTYPE

Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.

CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).

Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.